drugset
drugset / Trial / NCT03621280

Open-label Treatment in Cushing's Syndrome

NCT03621280 ↗

Phase 3 Completed 51 enrolled Cortendo AB
NaSingle-groupOpen-labelTreatment

Summary

This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.

Timeline

Start
2019-01-07
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Levoketoconazole Unknown 1200 mg —

Indications

endogenous Cushing syndrome